NovoCure Ltd.
- Country
- 🇯🇪Jersey
- Ownership
- Public
- Established
- 2000-01-01
- Employees
- 1.4K
- Market Cap
- -
- Website
- http://www.novocure.com
Clinical Trials
18
Trial Phases
5 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (15 trials with phase data)• Click on a phase to view related trials
TTFields General Routine Clinical Care in ndGBM Patients: a French Prospective Non-Interventional Study (TIGER France)
- Conditions
- Glioblastoma
- First Posted Date
- 2025-04-11
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- NovoCure Ltd.
- Target Recruit Count
- 430
- Registration Number
- NCT06924099
- Locations
- 🇫🇷
Chu Amiens Picardie, Amiens, France
🇫🇷Institut Sainte-Catherine, Avignon, France
🇫🇷Chu Saint Andre, Bordeaux, France
EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma
- Conditions
- Metastatic Pancreatic Ductal Adenocarcinoma
- Interventions
- First Posted Date
- 2024-04-29
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- NovoCure Ltd.
- Target Recruit Count
- 84
- Registration Number
- NCT06390059
- Locations
- 🇨🇿
University Hospital Hradec Kralove, Hradec Králové, Czechia
🇨🇿University Hospital Olomouc, Olomouc, Czechia
🇨🇿University Hospital Motol, Prague, Czechia
TIGER PRO-Active - Daily Activity, Sleep and Neurocognitive Functioning Study
- Conditions
- Glioblastoma
- First Posted Date
- 2021-01-22
- Last Posted Date
- 2023-01-10
- Lead Sponsor
- NovoCure Ltd.
- Target Recruit Count
- 500
- Registration Number
- NCT04717739
- Locations
- 🇩🇪
Universitätsklinikum Aachen, Aachen, Germany
🇩🇪Klinikum Aschaffenburg-Alzenau, Aschaffenburg, Germany
🇩🇪Universitätsklinikum Augsburg (AöR), Augsburg, Germany
Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant with RT & TMZ for the Treatment of Newly Diagnosed GBM
- Conditions
- Glioblastoma Multiforme
- First Posted Date
- 2020-07-15
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- NovoCure Ltd.
- Target Recruit Count
- 982
- Registration Number
- NCT04471844
- Locations
- 🇺🇸
Mary Bird Cancer Center Neuromedical Center, Baton Rouge, Louisiana, United States
🇺🇸Jersey Shore University Medical Center, Neptune, New Jersey, United States
🇺🇸Neuroscience Center, Philadelphia - University of Pennsylvania, Philadelphia, Pennsylvania, United States
Effect of Tumor Treating Fields (TTFields, 150 KHz) Concomitant with Chemotherapy As First Line Treatment of Unresectable Gastroesophageal Junction or Gastric Adenocarcinoma
- Conditions
- Gastric CancerGastroEsophageal Cancer
- Interventions
- First Posted Date
- 2020-02-24
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- NovoCure Ltd.
- Target Recruit Count
- 28
- Registration Number
- NCT04281576
- Locations
- 🇭🇰
Queen Mary Hospital, Hong Kong, Hong Kong
- Prev
- 1
- 2
- 3
- 4
- Next